The Effect of Progesterone and Synthetic Progestins on Serum- and Estradiol-Stimulated Proliferation of Human Breast Cancer Cells

Abstract

The results from the Women’s Health Initiative study on enhanced breast cancer risk in postmenopausal women using an estrogen/progestin combination clearly indicate the need for a comparison of different progestins with regard to cancer risk. To shed some light on this issue, we have investigated the influence of progesterone and various synthetic C19- and C21-progestins on cell proliferation of a human breast cancer cell line in vitro. Of special interested was the comparison of two different regimens commonly used in HRT, sequential and continuous combination with estradiol. We used the human breast cancer cell line MCF-7 as a model. Progesterone (P), chlormadinone acetate (CMA), dienogest (DNG), gestodene (GSD), 3-ketodesogestrel (KDG), levonorgestrel (LNG), medroxyprogesterone acetate (MPA), and norethisterone (NET) were investigated in the range of 0.01nm to 10 µM alone and in combination with 10 nM estradiol. Cell proliferation was measured after 7 days using the ATP chemosensitivity test. Tested alone, CMA, DNG, GSD, KDG, MPA and NET significantly stimulated cell proliferation, but only at high dosages. Sequentially combined with estradiol, only CMA inhibited cell proliferation over the whole concentration range. Slight effects were found for DNG, GSD and KDG, whereas P and MPA only showed an effect at the highest concentration. NET had no significant effect on cell proliferation. Continuously combined, all progestins exhibited an inhibitory effect over the whole concentration range. The most prominent effects were found for P, CMA, GSD, and KDG. Only slight effects were found for DNG, MPA and NET. Our in vitro results indicate that the influence on breast cancer risk using HRT in postmenopausal women might depend on the type of progestin used as well as on the regimen applied. However, the net inhibitory in vitro effect of the progestins at clinically relevant dosages is rather minimal, and whether progestins in general can reduce breast cancer risk in long-term treatment remains uncertain. Further clinical trials are urgently needed to clarify this issue.

Progestins - Combination with Estradiol - Proliferation - MCF-7 Cells

References

• 1 Flötotto T, Djahansouzi S, Gläser M, Hanstein B, Niederacher D, Brumm C, Beckmann M W. Hormones and hormone antagonists: Mechanisms of action in carcinogenesis of endometrial and breast cancer.  Horm Metab Res. 2001;  33 451-457
• 2 Writing Group for the Women's Health Initiative Investigators .Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002 288: 321-333
• 3 Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.  JAMA. 2000;  283 485-491
• 4 Ross R K, Paganini-Hill A, Wan P C, Pike M C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.  J Natl Cancer Inst. 2000;  92 328-332
• 5 Andreotti P E, Thornthwaite J T, Morse I S. ATP Tumor Chemosensitivity Assay. In: Stanley PE, Kricka LJ (eds.; ). Bioluminescence and Chemiluminescence: Current Status Chichester; J. Wiley & Sons 1991: 417-420
• 6 Magnusson C, Baron J A, Correia N, Bergström R, Adami H O, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy.  nt J Cancer. 1999;  81 339-344
• 7 Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark.  Int J Cancer. 1988;  42 832-838
• 8 Collaborative Group on Hormonal Factors in Breast Cancer .Breast cancer and hormone replacement therapy: collaaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997 350: 1047-1059
• 9 Schatz R W, Soto A M, Sonnenschein C. Effects of interaction between estradiol-17 beta and progesterone on the proliferation of cloned breast tumor cells (MCF-7 and T47D; ).  J Cell Physiol. 1985;  124 386-390
• 10 Poulin R, Baker D, Poirier D, Labrie F. Multiple actions of syntheticprogestins on the growth of ZR-75 - 1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonstic activities of steroids.  Breast Cancer Res Treat. 1991;  17 197-210
• 11 Katsuki Y, Shibutani Y, Aoki D, Nozawa S. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins.  Cancer. 1997;  79 169-176
• 12 Schoonen W GEJ, Joosten J WH, Kloosterboer H J. Effects of two classes of progestagens pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines.  J Steroid Biochem Mol Biol. 1995;  55 423-437
• 13 Jeng M H, Parker C J, Jordan V C. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.  Cancer Res. 1992;  52 6539-6546
• 14 van der Burg B, Kalkhoven E, Isbrücker L, DeLaat S W. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions.  J Steroid Biochem Mol Biol. 1992;  42 457-465
• 15 Cappelletti V, Miodini P, Fioravanti L, DiFronzo G. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines.  Anticancer Res. 1995;  15 2551-2556
• 16 Catherino W H, Jeng M H, Jordan V C. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.  Brit J Cancer. 1993;  67 945-952
• 17 Foidart J M, Colin C, Denoo X, Desreux J, Beliard A, Fournier S, de Lignieres B. Estradiol and progesterone regulate the proliferation of human breast epithelial cells.  Fertil Steril. 1998;  69 963-969
• 18 Hargreaves D F, Knox F, Swindell R, Potten C S, Bundred N J. Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy.  Br J Cancer. 1998;  78 945-949
• 19 Hofseth L J, Raafat A M, Osuch J R, Pathak D R, Slomski C A, Haslam S Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast.  J Clin Endocrinol Metab. 1999;  84 4559-4565
• 20 Wang S, Counterman L J, Haslam S Z. Progesterone action in normal mouse mammary gland.  Endocrinology. 1990;  127 2183-2189
• 21 Cline J M, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques.  Br Cancer Res Treat. 1998;  48 221-229
• 22 Svensson L O, Johnson S H, Olsson S E. Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil®, Trisequence®/Provera®, and Divina®. A randomised, single-blind, triple cross-over bioavailability study in menopausal women.  Maturitas. 1994;  18 229-238
• 23 Stanczyk F Z, Brenner P F, Mishell D R, Ortiz A, Gentzschein E KE, Goebelsmann U. A radioimmunoassay for norethindrone (NET): measurement of serum net concentrations following ingestion of NET-containing oral contraceptive steroids.  Contraception. 1978;  18 615-633
• 24 Meilahn E N, de Stavol B, Allen D S, Fentiman I, Bradlow H L, Stepkovic D W. et al . Do urinary oestrogen metabolites predict breast cancer ? Guernsey III cohort follow-up.  British Journal of Cancer. 1998;  78 1250-1255
• 25 Muti P, Bradlow H L, Micheli A, Krogh V, Freudenheim J L, Schunemann H J. et al . Estrogen metabolism and risk of breast cancer: a prospective study of 2 : 16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women.  Epidemiology. 2000;  11 635-640
• 26 Berstein L M, Tsyrlina E V, Kolesnik O S, Gamajunova V B, Adlercreutz H. Catecholestrogens excretion in smoking and non-smoking postmenopausal women receiving estrogen replacement therapy.  J Steroid Biochem Mol Biol. 2000;  72 143-147
• 27 Lippert C, Seeger H, Mueck A O. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells.  Life Sciences. in press
• 28 Seeger H, Mueck A O, Lippert T H. Estradiol metabolism during oral and transdermal estradiol replacement therapy in the postmenopause.  Horm Metab Res. 1998;  30 598-601
• 29 Seeger H, Mueck A O, Lippert T H. Effect of norethisterone acetate on estrogen metabolism in postmenopausal women.  Horm Metab Res. 2000;  32 436-439